

# The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study

Laura Delgado-Ortega<sup>1</sup> · Almudena González-Domínguez<sup>2</sup> · Josep María Borrás<sup>3</sup> · Juan Oliva-Moreno<sup>4</sup> · Eva González-Haba<sup>5</sup> · Salomón Menjón<sup>6</sup> · Pedro Pérez<sup>7</sup> · David Vicente<sup>8</sup> · Luis Cordero<sup>1</sup> · Margarita Jiménez<sup>2</sup> · Susana Simón<sup>1</sup> · Álvaro Hidalgo-Vega<sup>4</sup> · Carlota Moya-Alarcón<sup>1</sup>

Received: 22 August 2017 / Accepted: 6 June 2018

© The Author(s) 2018

## Abstract

**Objective** To assess the economic burden of epithelial ovarian cancer (EOC) in incident patients and the burden by disease stage in Spain.

**Methods** We developed a Markov model from a social perspective simulating the natural history of EOC and its four stages, with a 10-year time horizon, 3-week cycles, 3% discount rate, and 2016 euros. Healthcare resource utilization and costs were estimated by disease stage. Direct healthcare costs (DHC) included early screening, genetic counselling, medical visits, diagnostic tests, surgery, chemotherapy, hospitalizations, emergency services, and palliative care. Direct non-healthcare costs (DNHC) included formal and informal care. Indirect costs (IC) included labour productivity losses due to temporary and permanent leaves, and premature death. Epidemiology data and resource use were taken from the literature and validated for Spain by the OvarCost group using a Delphi method.

**Results** The total burden of EOC over 10 years was 3102 mill euros: 15.1% in stage I, 3.9% in stage II, 41.0% in stage III, and 40.2% in stage IV. Annual average cost/patient was €24,111 and it was €8,641; €14,184; €33,858, and €42,547 in stages I–IV, respectively. Of total costs, 71.2% were due to DHC, 24.7% to DNHC, and 4.1% to IC.

**Conclusions** EOC imposes a significant economic burden on the national healthcare system and society in Spain. Investment in better early diagnosis techniques might increase survival and patients' quality of life. This would likely reduce costs derived from late stages, consequently leading to a substantial reduction of the economic burden associated with EOC.

**Keywords** Epithelial ovarian cancer · Economic burden of disease · Healthcare resource utilization · Spain

## Introduction

Ovarian cancer (OC) is a rare disease but with a high mortality rate in women [1]. In 2012, the estimated number of new cases in Europe was 65,538 and accounted for a total of 42,716 deaths [2]. That year, the incidence and mortality of OC in Spain were estimated between 13.7 and 7.9 per 100,000 population, being the fifth most frequent cancer type in women and the sixth leading cause of mortality [1].

It is a heterogeneous disease and has many histological subtypes; however, the majority of cases (~90%) are of epithelial origin (EOC) [3]. The cause of OC is unknown, but many associated risk factors have been identified. It is predominantly a disease diagnosed in postmenopausal women with the majority of cases (> 80%) being diagnosed in women over 50 years [3]. A woman's reproductive history appears to contribute significantly to her risk of ovarian cancer, although the family history also plays an important role. Approximately, 11–15% of OC are associated with inherited predisposition, mainly related to germline mutations in *BRCA1/2* genes [4]. Age also constitutes a risk factor in those OC patients with *BRCA1/2* mutations, with the mean age of onset being significantly earlier in those with a *BRCA1* mutation (45 years) compared with over 60 years of age for those with a *BRCA2* mutation [5].

---

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1007/s10198-018-0986-y>) contains supplementary material, which is available to authorized users.

---

✉ Laura Delgado-Ortega  
laura.delgado@astrazeneca.com

Extended author information available on the last page of the article

Due to the non-specific symptomatology of the onset and despite continuous advances in hereditary OC identification to prevent it, most patients (75%) [6, 7] are diagnosed with an advanced stage of disease according to the International Federation of Gynaecology and Obstetrics (FIGO) classification [8]. Staging is related to survival and is the most important factor to assess the prognosis of the patient. According to the FIGO Annual Report, women diagnosed with EOC between 1999 and 2001, had a 5-year survival mean rate of 86.4% among those diagnosed at stage I, 69.9% for those at stage II, 34.3% at stage III, and 18.6% for those diagnosed at stage IV [9].

EOC has a major impact on patients' quality of life and implies an important economic burden for healthcare services, patients, and society in general, for several reasons. These patients are treated with a large and growing amount of healthcare resources such as hospitalizations, medical appointments, and chemotherapy treatments administrated in day hospital units, since they are diagnosed [10, 11]. Administration is usually expensive, not only because of medical resource consumption, but also because it requires time expenditure from experienced nurses on day hospital units [9, 12, 13]. Additionally, the own aetiology of the disease entails a high risk of hospitalization [14]. Also, women diagnosed with EOC are usually of working age, so labour productivity losses due to premature mortality and to permanent and temporary leaves are, therefore, deemed considerable [15, 16]. In addition, patients in their last stages are likely to require home care, usually provided by family members [17]; professional care and support activities provided by informal caregivers have a relevant opportunity cost, which from a societal perspective should be accounted for.

Despite the considerable costs described above, the economic burden of EOC from a societal perspective had been scarcely analysed in the international literature and, specifically, in Spain. Measuring this burden may be relevant for healthcare decision makers, as it provides useful information to assess the real magnitude of the benefits derived from the possible intervention programs and health strategies targeting the disease. Moreover, it offers a baseline for prevention policy planning, and health resources and social care allocation.

Therefore, the main objective of this study was to assess the economic burden of EOC in incident patients in Spain, as well as the burden by disease stage. It provides essential evidence about resource cost, their evolution over time, and the efficiency of new treatments at each disease stage for economic evaluations. The secondary objective was to raise awareness about the importance of this cancer among society and healthcare authorities.

## Methods

A Markov model was considered as the most appropriate method to simulate the progression of EOC, regarding the modelling approaches adopted in the previous economic studies and the nature of the disease [18, 19]. A societal perspective was adopted and only incident cases of EOC in Spain were included.

Epidemiology data, survival rates, healthcare resources used, personal care (formal and informal), and productivity losses to populate the model were obtained from a literature review, including international and national references. International data were used whenever local data were not available. Databases consulted were Medline/Pubmed, Embase, Medes, American Economic Association's Electronic Bibliography (EconLit), and other official databases.


All extracted data were afterwards contrasted and validated through a multidisciplinary expert group using the Delphi methodology. This included one individual online survey and two in-person meetings to reach final consensus. The OvarCost Expert Panel was composed of a gynaecologic oncologist, a clinical oncologist, a genetic counselling specialist, an oncology hospital pharmacist, a health economics specialist, and an epidemiologist involved in cancer management at regional and national level.

The Markov model was developed with three possible health states: *stable*, *post-progression*, and *death* (Fig. 1). The time horizon of the model was 10 years, which is enough considering the survival rate of the disease and all the cost and clinical consequences for all four stages. The cycle length used was 3 weeks (21 days), which is the length of a chemotherapy cycle. Patients entered the model after they were diagnosed with EOC in the *stable* state. A cycle after, they can either remain *stable*, become worse, and move to a *post-progression* state, or die. Those who progress remain in a *post-progression* state until they die. Mortality risk in patients may change depending on their health state (*stable* or *post-progression*) and their disease stages (I, II, III, and IV) (Fig. 1). It is considered that patients are allocated to a specific disease stage at the initial diagnosis, and it does not change throughout their disease.

## Population

Incident patients were estimated from years 2017 to 2026, using a linear model between 2015, 2020, and 2025 as per GLOBOCAN predictions [1]. Accordingly, 3497 women diagnosed with ovarian cancer were estimated for the first year, and as per epidemiology data, the majority of cases

**Fig. 1** Markov model structure  
*i* disease stages I, II, III, or IV.  
 $Prssi$  probability of remaining in “stable” state (Stage i),  $Pdssi$  probability of dying in “stable” state (Stage i),  $Ppssi$  probability to progress from “stable” state (Stage i),  $Prpsi$  probability of remaining in “post-progression” state (Stage i), and  $Pdpsi$  probability of dying in “post-progression” state (Stage i)



**Table 1** Epidemiology, patient characteristics, and treatment of EOC by disease stage

	Stage I	Stage II	Stage III	Stage IV
<i>Epidemiology of EOC</i>				
EOC incidence ( <i>n</i> , (% of total))	1155 (37%)	195 (6%)	1116 (35%)	681 (22%)
Median progression-free survival (years)*	18.33	6.25	2.00	1.60
Median overall survival (years)*	19.50	7.50	3.20	1.90
<i>Patient characteristics</i>				
Mean age at diagnosis (years)	57.4	62.4	64.9	68.1
Mean weight (kg)	65	67	65	66
Mean height (cm)	159	160	159	160
<i>Hospitalizations and emergencies every 6 months</i>				
Number of hospitalizations	1.2	1.2	2.1	2.1
Patients hospitalized (%)	15.4	15.4	48.2	48.2
Number of emergencies	1.5	1.5	1.7	1.7
Patients in emergency services (%)	23.1	23.1	22.2	22.2
<i>Treatment</i>				
None	0%	0%	3.10%	8.80%
Surgery	66.70%	19.80%	11.30%	8.80%
Neoadjuvant chemotherapy + surgery	0%	0%	14.40%	24.20%
Surgery + adjuvant chemotherapy	33.30%	80.20%	71.10%	58.20%
<i>Type of surgery</i>				
Laparotomy	100%	100%	100%	100%
Omentectomy	0%	6.38%	100%	100%
Abdominal total hysterectomy	100%	100%	100%	100%
Bilateral salpingo-oophorectomy	0%	100%	100%	100%
Lymphadenectomy	0%	0%	75%	100%

\*Own elaboration based on Heintz et al. [9]

EOC, epithelial ovarian cancer

(90%) are of epithelial origin [3]. Those were distributed by the four disease stages [20], as shown in Table 1. New cases diagnosed in the following years until 2026 were added each year assuming no changes in the distribution of disease stages over time. Incident patients' distribution by stage comes from population-based cancer registries [20].

## Transition probabilities

Transition probabilities depend on the disease stage assigned at diagnosis and the health state as patients enter the model. Death probability in the *stable* state (Pdss) was the mortality rate in the general Spanish female population [21] (Pnd, natural death probability). This mortality rate was estimated taking into account age at diagnosis and at each stage of the disease [15], as stated in Table 1, and its evolution over time; finally, it was transformed to probabilities as  $1 - \exp^{(\text{rate at age})}$ .

Transition probabilities from *stable* state to *post-progression* state (Ppss) (Eq. 1) were assessed by progression-free survival (PFS) curves for each disease stage, which were built based on an exponential distribution of median PFS (Table 1; Fig. 2a) [9].

**Equation 1.** Probability of transitioning from *stable* to *post-progression* state:

$$\text{Ppss} = 1 - \exp(-\lambda t); \text{ with } \lambda = -\frac{\ln(0.5)}{\text{me}_{\text{PFS}}}. \quad (1)$$

Transition probabilities of patients who remain *stable* (Prss) were calculated as the inverse of the probability of dying plus the transition probability of progressing from *stable* to *post-progression* state. Transition probabilities from *post-progression* to *death* (Pdps) were estimated as the difference between overall survival (OS) and PFS, plus the probability of natural death (Eq. 2) (Fig. 2b). OS curves were built using an exponential distribution, taking into

account the median OS at each stage published by Heintz et al. [9] (Table 1; Fig. 2b).

**Equation 2.** Probability of dying for patients at *post-progression* state (Pdps):


$$\text{Pdps} = 1 - \exp(-\lambda' t) + \text{Pnd}; \text{ with } \lambda' = -\frac{\ln(0.5)}{\text{me}_{\text{OS}} - \text{me}_{\text{PFS}}}. \quad (2)$$

Transition probabilities of the patients who remain at the *post-progression* state (Prps) were estimated as the inverse of the probability of dying for patients at *post-progression* state.

## Costs and resource use

Costs were expressed in 2016 Euros (Tables 1, 2 in Online Resource). Unit healthcare costs were the median value of the unit costs for each Autonomous Community in Spain [20–37]. Since the costs come from different years, they were updated to € 2016 using the corresponding inflation rate: a medicine consumer price index (CPI) of 0.77% for direct healthcare costs (DHC) [40] (except for pharmaceutical costs and tariffs from Autonomous Communities already actualised) and a general CPI increase of 1.97% for direct non-healthcare costs (DNHC) [40]. In the Markov model, the costs were discounted at an annual rate of 3%, according to Spanish health technology assessment recommendations [41]. An annual growth rate of 1% was considered for labour productivity loss [42]. The average annual cost per patient was assessed dividing the total cost by the number of patients (those who were alive at the beginning of the year plus the incident patients in that year). Model costs were categorised as DHC, DNHC, and indirect costs (IC).

DHC included diagnosis and follow-up tests, treatments, and palliative care. Testing required at diagnosis according to the Spanish Society of Gynaecology and Obstetrics [12] include ovarian biopsy, biochemical analysis and vaginal ultrasonography, among others. Regarding selection criteria



**Fig. 2** Survival curves by disease stage. Progression free survival (a) and overall survival (b)

to identify *BRCA* mutation, it was agreed by the panel group that 20% of patients with EOC are referred to *BRCA1/2* genetic test and genetic counselling, accounting two of these visits, before and after the test [43]. Of these patients, 5% are identified with the genetic mutation and an average of five family members are derived to genetic counselling [44], a transvaginal ultrasound and a blood test every 6 months to detect the tumour marker CA125 [43]. The patient's follow-up depends on their disease state. The frequency for follow-up testing may be lower in stable patients, depending on the period of time that they remain at this health estate [12]. The percentage of patients hospitalized and those who attend to the emergency department due to EOC were also considered by disease stage (Table 1) [14]. Treatment management depends on many factors, such as the spread of the tumour and the patient's clinical situation, being surgery or/and chemotherapy the standard of care [3, 9]. Treatment usually starts with the surgical excision of the tumour mass. Nevertheless, this procedure is not always possible and an interval debulking surgery is performed. This intervention is a surgical excision that takes place after patients have taken neoadjuvant chemotherapy [12]. Most patients receive adjuvant chemotherapy. However, patients in stages Ia and Ib do not need chemotherapy after surgery and only remain under clinical observation [12]. The type of surgery depends on the size and the spread of the tumour, and on whether or not the woman is planning to get pregnant in the future [12, 13].

Clinical experts panel classified chemotherapy as: (1) neoadjuvant: patients who receive 3 cycles of paclitaxel in combination with carboplatin before surgery and complete their treatment with other 3 cycles of chemotherapy [12]; (2) adjuvant: chemotherapy administered after surgery in the *stable* state (stages I, II, and III); (3) post-progression: chemotherapy administered at the *post-progression* state (stages I and II); and (4) advanced: chemotherapy administered at the *post-progression* states at stage III and at both states at stage IV (Table 1).

The recommended drugs used are based on the EOC treatment recommended by SEGO guidelines [12]: paclitaxel, carboplatin, doxorubicin, bevacizumab, cisplatin, gemcitabine, topotecan, trabectedin, and docetaxel. Its usage was accounted based on its market share [45]. Doses were calculated according to the usual clinical practice and product labels [46–54] (Table 4 in Online Resource). Dose of carboplatin [47] was determined using the Calvert formula [55]. Du Bois et Du Bois formula was used to calculate the body surface area when necessary [56] (Table 3 in Online Resource). Patients' height and weight were consulted in Spanish National Health Survey according to the mean age at diagnosis of each stage disease [15, 57] (Table 1). Drug costs were calculated using the list price (LP) [58], including Royal Decree Law 8/2010 deduction rate, when necessary, and a 4% of the value-added tax (VAT) entitled for Spain

[58–61]. For intravenous drugs, the model also considered non-vials optimization and the cost of administration for each drug (€0.32 per minute [62]): time of administration required for each one [46–53] in the day hospital plus the cost of the 30-min preparation (Table 3 in Online Resource).

Palliative care is given to the patients in their last 48 days of life [63]. Up to 93.3% of the patients receive follow-up care at outpatient hospitals, while the remaining (6.7%) are assisted by palliative home care team [64]. Patients need a mean of 9.5 home visits of palliative-care services, while those who receive follow-up at the outpatient hospital are seen by a nurse [63]. In both cases, patients also pay four visits, on average, to the primary-care doctor [63] and they spent their terminal phase of their illness at home (59.6%) or at the hospital (40.4%) [65]. The last 3 days of this terminal phase, patients stay at home [66], and they are visited twice a day by a nurse [67]. Of these, 14% receive sedation [66]. The costs of visits [22–39] and drugs used in the palliative-care phase were also considered [58–61, 68–71] (Tables 1, 4 in Online Resource).

DNHC considered were formal care costs (i.e., professional care financed by private or public funds) and informal care costs given at home (non-remunerated care from relatives or friends). Based on the literature, it was assumed that 17.4% of the patients received private care, 9.5% public care [63], and 93.4% received informal care [72] throughout their last 48 days of life [63]. On average, it was considered that public caregivers spent 1.5 h providing care [63], private caregivers 8 h [63], and informal caregivers 10.3 h [17]. According to the proxy good method [73], hourly wage for formal and informal caregivers was equally valued, €13.56 [74].

Lost labour productivity due to temporary or permanent leave and premature death were included as indirect costs (IC), using the human-capital method [75–78]. At some point in the progress of the disease, patients with EOC become unable to develop their labour activities [79, 80]. Overall, 30% of *stable* patients lose 60 days due to temporary leave, while the remaining 70% lose over 70 days [45]. It was assumed that at advanced stages, patients are on sick leave, since progression starts until age of retirement (65 years). In case the patient's death occurs before 65 years, sick leave period is assumed to last between the beginnings of the disease progression until patient dies. Patients on sick leave for more than 1 year were considered to be in permanent leave [81]. Labour productivity loss caused by premature death included lost productivity of patients who die before 65 years of age [21, 79, 82, 83]. The percentage of women employed and their respective salaries are used to estimate labour productivity losses (Table 5 in Online Resource).

## Sensitivity analysis

Deterministic and univariate sensitivity analyses, including ten different scenarios, were conducted to examine the model's robustness. According to the OvarCost Expert Panel, different scenarios were built based on the possible variation of the most sensitive parameters: percentage of patients who receive genetic counselling (from 35 to 70%), patients weight ( $\pm 10\%$ ), growth productivity discount rate on (from 0 to 2%), manufacturer's drug price ( $-10\%$ ), discount drug rate (from 0 to 6%), tests and medical visits cost (maximum and minimum prices in the Autonomous Communities), age at time of diagnosis ( $\pm 10\%$ ), bevacizumab dose recommendation (7.5 mg/kg), caregiver's salary/informal care assessment per hour (€7.5) [84], and informal care hours received ( $\pm 30\%$ ).

## Results

The total economic burden of EOC in Spain was estimated in 3102 million euros (mill€) in 10 years. Stages I and II represented around 19% of the total cost of the disease each year, while stages III and IV accounted for 41 and 40%, respectively (Table 2). The average annual cost per patient was €24,111, being the greatest cost the corresponding to patients in stage disease IV (€42,547). By cost type, most of the economic burden of EOC was due to DHC (71.2%) being the DNHC 24.7% and IC 4.1% of the total, since most patients are diagnosed over 40 years of age. However, IC are more relevant at early stages (23.2% at stage I and 7.2% at stage II) (Fig. 3a; Table 2).

DHC were estimated in 2208 mill€ in 10 years. The average annual cost per patient was €17,501. The most important cost categories were advanced chemotherapy (909.9 mill€), hospitalizations (812.5 mill€), and surgery (204.0 mill€). Together, these represented around 87.2% of DHC. The average annual cost per patient was €6657.6 for advanced chemotherapy; €6304.1 for hospitalizations, and €2024.6 for surgeries (Table 2). Average annual costs per patient increased as the cancer spread, with DHC at stage IV being around eight times higher than DHC at stage I (Fig. 3b).

DNHC represented 766.7 mill€ in 10 years. The average annual cost per patient was €5608. Patients at stages II, III, and IV were substantially assisted by informal carers. Informal care implied 98.6% of DNHC at any stage (Table 2) and reached €12,437.4 per patient per year at stage III (Fig. 3c).

Lost labour productivity was estimated in 127 mill€ in 10 years, of which temporary leave accounted for 40.9%; permanent leave for 5.4%, and premature death for 53.7%. Most losses occurred at early disease stage, with 85.5% in stage I (Fig. 3d). Labour productivity losses amounted to

€1002.1 per patient every year. IC annual per patient was €1990.6 at stage I and €1198.1 at stage II. However, a lower productivity cost was observed for patients at stages III and IV (€342.9 at stage III and € 0 at stage IV) (Table 2).

## Sensitivity analysis

The sensitivity analysis was based on the percentage of patients who receive genetic counselling, patients weight, discount rate on growth productivity, and manufacturer price had almost no impact on the global burden of the disease (changed the average annual cost per patient in between –2.9 and 2.6%).

Figure 4 shows sensitivity analysis results which substantially modified the global study results. The average annual cost per patient (€24,111) fluctuates between €21,151 and €28,281, which influences the global burden between 2605 and 3734 mill€ in 10 years, being in the base case analysis 3102 mill€.

## Discussion

To our knowledge, this is the first study that is close to estimating the economic impact of EOC in Spain considering DHC as well as DNHC and IC involved in patient care. Our estimates indicate that the global average cost per patient with EOC may amount to €24,111 every year in Spain, with significant differences by disease stages, from €8,641 at stage I to €42,547 at stage IV. This result was expected as most of the patients are diagnosed at advanced stages of the disease and those are likely to need more healthcare resources and home care.

Research on the economic burden of OC is scarce in scientific literature. However, Kim et al assessed the annual DHC per patient in Hungary, Serbia, and Slovakia [18]. Their approach was based on different health states: surgical treatment; first-line, second-line, and third-line chemotherapy; and monitoring/follow-up and palliative care/death. However, we calculated the DHC per stage of disease, according to the FIGO classification [8]. This latter methodology allows estimating the resources that patients require, considering their stage at diagnosis. It also makes easier the comparison to future studies regarding the burden of OC in other countries.


The growing scientific literature on informal care costs suggests the relevance of this social resource in the case of many diseases and injuries [85, 86]. One of the strongest findings of our study is the estimation of informal care costs associated with EOC. To our knowledge, this is the first study that estimates the economic impact of caregiving among EOC patients in Spain. Our results show that costs of informal care represent 24.4% of the global burden of EOC,

**Table 2** Results of the model: direct healthcare costs, direct non-healthcare costs, and indirect costs by stage

	Stage I		Stage II		Stage III		Stage IV	
	Total cost, € (%)	Average annual cost/patient (€)	Total cost, € (%)	Average annual cost/patient (€)	Total cost, € (%)	Average annual cost/patient (€)	Total cost, € (%)	Average annual cost/patient (€)
<b>Direct healthcare costs (DHC)</b>								
Opportunistic screening test (patients)	3,088,335 (0.66)	88.90	519,790 (0.45)	92.46	2,984,717 (0.23)	103.10	2,569,116 (0.21)	119.03
Genetic counselling (relatives)	1,477,440 (0.32)	26.63	248,570 (0.21)	28.78	1,427,697 (0.11)	35.33	1,105,642 (0.09)	35.09
Diagnosis	6,845,283 (1.46)	197.04	1,152,114 (0.99)	204.94	15,650,937 (1.23)	540.63	13,471,654 (1.08)	624.17
Follow-up visits and test	12,550,184 (2.68)	230.70	2,448,326 (2.10)	288.28	16,131,636 (1.27)	414.67	7,449,071 (0.60)	260.89
Surgery	33,386,327 (7.12)	794.29	9,138,573 (7.84)	1,550.41	87,624,527 (6.89)	2,879.72	73,843,438 (5.93)	3,211.65
Chemotherapy	73,429,456 (15.66)	1,399.93	28,018,052 (24.02)	3,517.86	223,313,473 (17.57)	6,274.45	725,107,595 (58.21)	23,527.41
Hospitalizations	104,089,546 (22.20)	1,915.55	15,453,906 (13.25)	1,879.60	377,473,449 (29.69)	10,199.17	315,441,267 (25.32)	10,197.08
Emergency services	6,240,086 (1.33)	114.84	926,449 (0.79)	112.68	4,249,286 (0.33)	114.81	3,550,979 (0.29)	114.79
Palliative care	4,793,722 (1.02)	76.47	1,912,383 (1.64)	203.48	21,116,270 (1.66)	515.37	10,077,388 (0.81)	527.30
Total DHC	245,900,380 (52.45)	4,844.35	59,818,164 (51.29)	7,878.49	749,971,992 (59.00)	21,077.26	1,152,616,149 (92.54)	38,617.41
<b>Direct non-healthcare costs (DNHC)</b>								
Public formal care	126,432 (0.03%)	1.99	50,370 (0.04%)	5.30	553,693 (0.04%)	13.39	259,010 (0.02%)	13.33
Private formal care	1,235,043 (0.26%)	19.45	492,033 (0.42%)	51.74	5,408,711 (0.43%)	130.82	2,530,115 (0.20%)	130.23
Informal care	112,708,919 (24.04%)	1,784.14	47,855,777 (41.03%)	5,049.87	505,313,452 (39.75%)	12,293.17	90,186,328 (7.24%)	3,785.87
Total DNHC	114,070,394 (24.33%)	1,805.58	48,398,180 (41.50%)	5,106.91	511,275,856 (40.22%)	12,437.38	92,975,453 (7.46%)	3,929.43
<b>Indirect costs (IC)</b>								
Temporary disability	37,936,056 (8.09%)	973.23	4,136,727 (3.55%)	668.13	9,975,732 (0.78%)	342.54	0 (0%)	0
Permanent disability	6,129,363 (1.31%)	102.23	773,669 (0.66%)	94.37	0 (0.00%)	0.00	0 (0%)	0
Premature mortality	64,769,698 (13.82%)	915.14	3,496,382 (3.00%)	435.63	10,774 (0%)	0.38	0 (0%)	0
Total IC	108,835,116 (23.22%)	1,990.61	8,406,778 (7.21%)	1,198.13	9,986,506 (0.79%)	342.92	0 (0.00%)	0
Total	468,805,889 (100%)	8,640.53	116,623,122 (100%)	14,183.54	1,271,234,354 (100%)	33,857.56	1,245,591,602 (100%)	42,546.84

and are higher in stage III. Finally, we found that IC represent the smallest proportion of the global burden (4.1%), and they are significantly higher at early stage of the disease (stage I), when women are more likely to be of working age and less likely to die prematurely, than at later stages.

Our study is not without limitations. First, due to the lack of information about this cancer in Spain, the PFS curves from other countries were deemed similar enough to be used for our country. In addition, some data referring to all types of OC were used, since EOC accounts for 90% of the OC




**Fig. 3** Cost distribution results by disease stage. Total costs (a), direct healthcare costs (b), direct non-healthcare costs (c) and indirect costs (d)

in general. Those data were considered representative and valid. Second, as neither national nor international references were found regarding average height and weight of patients with EOC by disease stage, our model included the average weight and height of women with any cancer by age at diagnosis in Spanish National Health Survey. However, the sensibility analysis showed that the weight of the patients had almost no impact on the global burden of EOC. Third, because of this lack of data availability about the patients in Spain, we adopted an incidence model approach. However, since this method does not include the patients previously diagnosed, and it may underestimate the burden of EOC. Fourth, our model considered that vials were used only once, although in Spanish practice, patients are usually gathered in day hospitals to optimise drug vials usage. Optimization of vials would decrease the global cost of treatment. Fifth, the percentage of patients who needed informal care was obtained from an observational study about patients with haematological neoplasia developed in Spain, whose situation may be different compared to those with EOC. Finally, our study does not quantify the substantial psychological load that caregivers may suffer from.

Despite its limitations, we believe that this study represents the most complete economic burden of EOC performed to date in Spain. Our results suggest that the disease's economic impact on healthcare resources significantly increases with the stage at which the cancer is diagnosed. Investment in the development and evaluation of techniques for early diagnosis may imply higher survival rates and a substantial reduction in the economic burden of EOC, due to possible cost savings at advanced disease stages. Besides, this study emphasizes the importance of informal care in the global burden of the disease, especially in advanced stages. In conclusion, our results highlight the importance of analysing the economic consequences of EOC from a societal perspective, providing an insight into the distribution of this cancer costs by stage, with the final aim of informing healthcare services planning appropriately.

**Fig. 4** Total cost tornado diagram (a) and the average annual cost per patient of epithelial ovarian cancer (b). DBeva dose of bevacizumab, HIC hours of informal care, CS/h caregiver salary per hour, CT and MD cost of tests and medical visits, DR discount rate on growth productivity



## Compliance with ethical standards

**Funding** This study was funded by AstraZeneca (AstraZeneca Farmacéutica Spain S.A.), although AstraZeneca did not influence on the results of the study.

**Conflict of interest** Authors Laura Delgado-Ortega, Luis Cordero, Susana Simon and Carlota Moya-Alarcón are employees of AstraZeneca. Authors Almudena González-Domínguez and Margarita Jiménez work in Weber, enterprise that received fees from AstraZeneca. Authors Josep María Borrás, Juan Oliva-Moreno, Eva González-Haba, Salomón Menjón, Pedro Pérez and David Vicente have received honorarium from AstraZeneca Spain, during the conduct of the study. Author Álvaro Hidalgo-Vega has no potential conflict of interest.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

## References

1. Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D., Forman, D., Bray, F.: Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, <http://globocan.iarc.fr/Default.aspx>
2. World Health Organization (WHO): EU CAN Factsheets|Ovarian cancer, <http://eco.iarc.fr/eucan/CancerOne.aspx?Cancer=27&Gender=2#block-mapc-f>
3. Ledermann, J.A., Raja, F.A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., Sessa, C.: Group, on behalf of the E.G.W.: Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. **24**, vi24–vi32 (2013). <https://doi.org/10.1093/annonc/mdt333>
4. Llort, G., Chirivella, I., Morales, R., Serrano, R., Sanchez, A.B., Teulé, A., Lastra, E., Brunet, J., Balmaña, J., Grañá, B.: Group, O. behalf of the S.H.C.W.: SEOM clinical guidelines in hereditary breast and ovarian cancer. Clin. Transl. Oncol. **17**, 956 (2015). <https://doi.org/10.1007/s12094-015-1435-3>
5. Jelovac, D., Armstrong, D.K.: Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J. Clin. **61**, 183–203 (2011). <https://doi.org/10.3322/caac.20113>

6. Hennessy, B.T., Coleman, R.L., Markman, M.: Ovarian cancer. *Lancet* **374**, 1371–1382 (2009). [https://doi.org/10.1016/S0140-6736\(09\)61338-6](https://doi.org/10.1016/S0140-6736(09)61338-6)
7. Guarneri, V., Piacentini, F., Barbieri, E., Conte, P.F.: Achievements and unmet needs in the management of advanced ovarian cancer. *Gynecol. Oncol.* **117**, 152–158 (2010). <https://doi.org/10.1016/j.ygyno.2009.11.033>
8. Mutch, D.G., Prat, J.: 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. *Gynecol. Oncol.* **133**, 401–404 (2014). <https://doi.org/10.1016/j.ygyno.2014.04.013>
9. Heintz, A., Odicino, F., Maisonneuve, P., Quinn, M., Benedet, J., Creasman, W., Ngan, H., Pecorelli, S., Beller, U.: Carcinoma of the Ovary. *Int. J. Gynecol. Obstet.* **95**(Supplement 1), S161–S192 (2006). [https://doi.org/10.1016/S0020-7292\(06\)60033-7](https://doi.org/10.1016/S0020-7292(06)60033-7)
10. Ignatyeva, V.I., Derkach, E.V., Avxentyeva, M.V., Omelyanovsky, V.V.: The cost of melanoma and kidney, prostate, and ovarian cancers in Russia. *Value Health Reg. Issues.* **4**, 58–65 (2014). <https://doi.org/10.1016/j.vhri.2014.07.002>
11. Bifulco, G., De Rosa, N., Tornesello, M.L., Piccoli, R., Bertrando, A., Lavitola, G., Morra, I., Sardo, A.D.S., Buonaguro, F.M., Nappi, C.: Quality of life, lifestyle behavior and employment experience: a comparison between young and midlife survivors of gynecology early stage cancers. *Gynecol. Oncol.* **124**, 444–451 (2012). <https://doi.org/10.1016/j.ygyno.2011.11.033>
12. Sociedad Española de Ginecología y Obstetricia (SEGO): Oncoguía SEGO. Cáncer epitelial de ovario 2014. Guías de práctica clínica en cáncer ginecológico y mamario. (2014)
13. Boyd, L.R., Novetsky, A.P., Curtin, J.P.: Ovarian cancer care for the underserved: are surgical patterns of care different in a public hospital setting? *Cancer* **117**, 777–783 (2011). <https://doi.org/10.1002/cncr.25490>
14. McCorkle, R., Jeon, S., Ercolano, E., Schwartz, P.: Healthcare utilization in women after abdominal surgery for ovarian cancer. *Nurs. Res.* **60**, 47–57 (2011). <https://doi.org/10.1097/NNR.0b013e3181ff77e4>
15. Maringe, C., Walters, S., Butler, J., Coleman, M.P., Hacker, N., Hanna, L., Mosgaard, B.J., Nordin, A., Rosen, B., Engholm, G., Gjerstorff, M.L., Hatcher, J., Johannessen, T.B., McGahan, C.E., Meechan, D., Middleton, R., Tracey, E., Turner, D., Richards, M.A., Rachet, B.: Stage at diagnosis and ovarian cancer survival: evidence from the international cancer benchmarking partnership. *Gynecol. Oncol.* **127**, 75–82 (2012). <https://doi.org/10.1016/j.ygyno.2012.06.033>
16. Vicente-Herrero, M.T., Terradillos-García, M.J., Ramírez-Íñiguez\_de la Torre, M.V., Capdevila-García, C., López-González, L.M.: AA: Colorectal cancer in Spain: temporary disability and preventive occupational strategies. *Rev. Gastroenterol. México* **78**, 75–81 (2013). <https://doi.org/10.1016/j.rgmx.2012.10.005>
17. Yabroff, K.R., Kim, Y.: Time costs associated with informal caregiving for cancer survivors. *Cancer* **115**, 4362–4373 (2009). <https://doi.org/10.1002/cncr.24588>
18. Kim, K., Hernlund, E., Hernadi, Z., Révész, J., Pete, I., Szánthó, A., Bodnar, L., Madry, R., Timorek-Lemiesczuk, A., Bozanovic, T., Vasovic, S., Tomasevic, Z., Zivaljevic, M., Pazin, V., Minárik, T., Garanová, H., Helpianska, L., Justo, N.: Treatment patterns, health care utilization, and costs of ovarian cancer in Central and Eastern Europe using a Delphi panel based on a retrospective chart review. *Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc.* **23**, 823–832 (2013). <https://doi.org/10.1097/IGC.0b013e318291e8ca>
19. Sonnenberg, F.A., Beck, J.R.: Markov models in medical decision making: a practical guide. *Med. Decis. Making.* **13**, 322–338 (1993). <https://doi.org/10.1177/0272989X9301300409>
20. Ovarian cancer incidence statistics, <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer/incidence>
21. Instituto Nacional de Estadística: Tasa de mortalidad. Tablas de mortalidad de la población de España 1991–2016. Indicadores Demográficos Básicos (2016). <http://www.ine.es/jaxi/menu.do?type=pcaxis&path=/t20/p319a/&file=inebase>
22. Resolución de 30 de julio de 2012, de la Dirección de Gerencia del Servicio Aragonés de Salud, sobre revisión de las tarifas a aplicar por la prestación de servicios sanitarios a terceros obligados al pago o a usuarios sin derecho a asistencia sanitaria en la Comunidad Autónoma de Aragón. Boletín Oficial de Aragón núm. 156, 10 agosto de 2012 (2012)
23. Orden 731/2013, de 6 de septiembre, del Consejero de Sanidad, por la que se fijan los precios públicos por la prestación de los servicios y actividades de naturaleza sanitaria de la Red de Centros de la Comunidad de Madrid. Boletín Oficial de la Comunidad de Madrid núm. 215, 10 septiembre de 2013 (2013). [http://w3.bocm.es/boletin/CM\\_Orden\\_BOBCM/2013/09/10/BOCM-20130910-1.PDF](http://w3.bocm.es/boletin/CM_Orden_BOBCM/2013/09/10/BOCM-20130910-1.PDF)
24. Resolución de 30 de marzo de 2015, de la Directora, por la que se modifica la cuantía de los precios públicos de servicios sanitarios previstos en el Decreto 81/2009, de 16 de junio, que establece los precios públicos de los servicios sanitarios prestados por el Servicio Canario de la Salud y fija sus cuantías. Boletín Oficial de Canarias núm. 70, 14 abril de 2015 (2015)
25. Orden SAN/12/2011, de 20 de abril, por la que se fijan las cuantías de los precios públicos de los Servicios Sanitarios prestados por el Servicio Cántabro de Salud. Boletín Oficial de Cantabria núm. 85, 5 de mayo de 2011 (2011). <http://www.saludcantabria.es/uploads/pdf/consejeria/boletinesCVEordendeprecios.pdf>
26. Resolución del Director General del Servei de Salut de modificación del anexo I de la Orden de la Conselleria de Salut i Consum de 22 de diciembre de 2006. Butlletí Oficial de les Illes Balears núm. 89, 1 de Julio de 2014 (2014). <http://www.caib.es/eboibfront/es/2014/8339/542720/resolucion-del-director-gener-al-del-servi-de-salu>
27. Orden de 18 de noviembre de 2015, por la que se modifica la Orden de 14 de octubre de 2005, por la que se fijan los precios públicos de los servicios sanitarios prestados por Centros dependientes del Sistema Sanitario Público de Andalucía (2015)
28. Resolución 88/2010, de 3 de mayo, del director gerente del Servicio Navarro de Salud-Osasunbidea. Por la que se actualizan las tarifas por prestación de servicios en los centros y establecimientos asistenciales del Servicio Navarro de Salud-Osasunbidea núm. 71, 11 de junio de 2010 (2010)
29. Decreto 120/2013, de 27 de diciembre, por lo que se actualizan los precios públicos por cuantía fija. Boletín Oficial del Principado de Asturias núm. 301 de 31 de diciembre de 2013 (2014)
30. Orden 17/2014, de 16 de noviembre de 2014, de la Consejería de Administración Pública y Hacienda por la que se establece y regula el precio público por los servicios sanitarios prestados a particulares en los centros del Servicio Riojano de Salud. Boletín Oficial de La Rioja núm. 156, 19 diciembre de 2014 (2014). [http://ias1.larioja.org/boletin/Bor\\_Boletin\\_visor\\_Servlet?referencia=1902409-1-PDF-486979](http://ias1.larioja.org/boletin/Bor_Boletin_visor_Servlet?referencia=1902409-1-PDF-486979)
31. Orden de 17/11/2014, de la Consejería de Sanidad y Asuntos Sociales, por la que se establecen los precios públicos de la asistencia sanitaria y de los servicios prestados en la red de centros sanitarios dependientes del Servicio de Salud de Castilla-La Mancha. Diario Oficial de Castilla-La Mancha núm. 226, 21 noviembre de 2014 (2014). [http://doctr.castillalamancha.es/portaldocm/descargarArchivo.do?ruta=2014/11/21/pdf/2014\\_15022.pdf&tipo=rutaDocm](http://doctr.castillalamancha.es/portaldocm/descargarArchivo.do?ruta=2014/11/21/pdf/2014_15022.pdf&tipo=rutaDocm)
32. Diario Oficial de la Generalitat Valenciana núm 970, de 31 de enero de 2014. Ley 5/2013, de 23 de diciembre, de Medidas Fiscales, de Gestión Administrativa y Financiera, y de Organización de la Generalitat (2013). <http://www.boe.es/boedias/2014/01/31/pdfs/BOE-A-2014-970.pdf>

33. Orden SLT/30/2013, de 20 de febrero, por la que se aprueban los precios públicos del Servicio Catalán de la Salud. Diario Oficial de la Generalitat de Catalunya núm. 6323, 26 febrero de 2013 (2013)
34. Decreto 56/2014, de 30 de abril, por el que se establecen las tarifas de los servicios sanitarios prestados en los centros dependientes del Servicio Gallego de Salud y en las fundaciones públicas sanitarias. Diario Oficial de Galicia núm. 96, 21 de mayo (2014)
35. Orden de 3 de febrero de 2015 de la Consejería de Economía y Hacienda, por la que se publican las tarifas de las tasas y precios públicos aplicables en 2015. Boletín Oficial de la Región de Murcia núm. 33, 10 febrero de 2015 (2015). <http://www.borm.es/borm/documento?obj=anu&id=725195>
36. Boletín Oficial del Estado (BOE) núm. 180, 29 de julio de 2013. Resolución de 19 de julio de 2013, del Instituto Nacional de Gestión Sanitaria, sobre revisión de precios a aplicar por los centros sanitarios del Instituto Nacional de Gestión Sanitaria en Ceuta y Melilla, por las asistencias prestadas en los supuestos cuyo importe ha de reclamarse a los terceros obligados al pago o a los usuarios sin derecho a la asistencia sanitaria de la Seguridad Social, así como por los servicios prestados por el Centro Nacional de Dosimetría y por la reproducción de documentos de la biblioteca de la entidad gestora (2013)
37. Decreto 25/2010, de 17 de junio, por el que se actualizan los precios públicos por actos asistenciales y servicios sanitarios prestados por la Gerencia Regional de Salud de Castilla y León. Boletín Oficial de Castilla y León núm. 119, 23 de junio de 2010 (2010)
38. Resolución de 17 de febrero de 2015, del Consejero, por la que se publican las tarifas actualizadas de las tasas y precios públicos de la Comunidad Autónoma de Extremadura, en virtud de lo dispuesto en la Ley de Presupuestos Generales de la Comunidad Autónoma de Extremadura para el 2015. Diario Oficial de Extremadura núm 36, 23 de febrero, 2015 (2015)
39. Acuerdo de 23 de febrero de 2015, del Consejo de administración del ente público Osakidetza, por el que se aprueban las tarifas por prestación de servicios sanitarios y docentes a terceros obligados al pago durante el ejercicio 2015 (2015). [http://www.euskadi.eus/contenidos/informacion/libro\\_tarifas/es\\_libro/adjuntos/tarifas2015.pdf](http://www.euskadi.eus/contenidos/informacion/libro_tarifas/es_libro/adjuntos/tarifas2015.pdf)
40. Instituto Nacional de Estadística (INE): Nivel y condiciones de vida (IPC)/Índices de precios de consumo y vivienda/Índice de precios de consumo/Últimos datos, [http://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica\\_C&cid=1254736176802&menu=ultiDatos&idp=1254735976607](http://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=1254736176802&menu=ultiDatos&idp=1254735976607)
41. Bastida, J.L., Oliva, J., Antoñanzas, F., García-Altés, A., Gisbert, R., Mar, J., Puig-Junoy, J.: Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias. *Gac. Sanit.* **24**, 154–170 (2010)
42. Oliva-Moreno, J.: Loss of labour productivity caused by disease and health problems: what is the magnitude of its effect on Spain's Economy? *Eur. J. Health Econ.* **HEPAC**, 13, 605–614 (2012). <https://doi.org/10.1007/s10198-011-0344-9>
43. Agència d'Avaluació de Tecnologia i Recerca Mèdiques (AATRM): Guía de Práctica clínica. Oncoguía del Consejo y asesoramiento genéticos en el cáncer hereditario. Versión completa. Agència d'Avaluació de Tecnologia i Recerca Mèdiques (AATRM) (2006)
44. Balmaña, J., Sanz, J., Bonfill, X., Casado, A., Rué, M., Gich, I., Díez, O., Sabaté, J.M., Baiget, M., Alonso, M.C.: Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost and cost-effectiveness ratio. *Int. J. Cancer* **112**, 647–652 (2004). <https://doi.org/10.1002/ijc.20458>
45. Drug shares. Quarter 3 data. Ipsos MORI Social Research Health, <https://www.ipsos-mori.com/researchspecialisms/socialresearch/specareas/nhspublichealth.aspx>
46. Bevacizumab. Avastin. Ficha Técnica. European Medicines Agency (EMA) (2017). [http://www.ema.europa.eu/docs/es\\_ES/document\\_library/EPAR\\_-\\_Product\\_Information/human/000582/WC500029271.pdf](http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf)
47. Carboplatino. Ficha Técnica. Agencia Española del Medicamento (AEMPS) (2012). [http://www.aemps.gob.es/cima/pdfs/es/ft/70707/FT\\_70707.pdf](http://www.aemps.gob.es/cima/pdfs/es/ft/70707/FT_70707.pdf)
48. Gemcitabina. Ficha Técnica. Agencia Española del Medicamento (AEMPS) (2014). [http://www.aemps.gob.es/cima/pdfs/es/ft/76166/FT\\_76166.pdf](http://www.aemps.gob.es/cima/pdfs/es/ft/76166/FT_76166.pdf)
49. Paclitaxel. Ficha Técnica. Agencia Española del Medicamento (AEMPS) (2014). [http://www.aemps.gob.es/cima/pdfs/es/ft/73010/FT\\_73010.pdf](http://www.aemps.gob.es/cima/pdfs/es/ft/73010/FT_73010.pdf)
50. Topotecan. Ficha Técnica. Agencia Española del Medicamento (AEMPS) (2015). [http://www.aemps.gob.es/cima/pdfs/es/ft/72892/FT\\_72892.pdf](http://www.aemps.gob.es/cima/pdfs/es/ft/72892/FT_72892.pdf)
51. Trabectedina. Yondelis. Ficha Técnica. European Medicines Agency (EMA) (2012). [http://www.ema.europa.eu/docs/es\\_ES/document\\_library/EPAR\\_-\\_Product\\_Information/human/000773/WC500045832.pdf](http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000773/WC500045832.pdf)
52. Doxorubicina. Caelyx. Ficha Técnica. Agencia Española del Medicamento (2006). [http://www.ema.europa.eu/docs/es\\_ES/document\\_library/EPAR\\_-\\_Product\\_Information/human/000089/WC500020180.pdf](http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000089/WC500020180.pdf)
53. Cisplatino. Ficha Técnica. Agencia Española del Medicamento (AEMPS) (2014). [http://www.aemps.gob.es/cima/pdfs/es/ft/72609/FT\\_72609.pdf](http://www.aemps.gob.es/cima/pdfs/es/ft/72609/FT_72609.pdf)
54. Docetaxel. Ficha Técnica. Agencia Española del Medicamento (AEMPS) (2010). [http://www.aemps.gob.es/cima/pdfs/es/ft/74733/FT\\_74733.pdf](http://www.aemps.gob.es/cima/pdfs/es/ft/74733/FT_74733.pdf)
55. Calvert, A.H., Newell, D.R., Gumbrell, L.A., O'Reilly, S., Burnell, M., Boxall, F.E., Siddik, Z.H., Judson, I.R., Gore, M.E., Wiltshaw, E.: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **7**, 1748–1756 (1989)
56. Du Bois, D., Du Bois, E.F.: A formula to estimate the approximate surface area if height and weight be known. *1916. Nutr. Burbank Los Angel. Cty. Calif.* **5**, 303–311 (1989) (discussion 312–313)
57. Instituto Nacional de Estadística: Microdatos de la encuesta nacional de salud (2012)
58. Consejo General de Colegios Oficiales de Farmacéuticos: Botplusweb.portalfarmacia.com. BOT Plus 2. Base de Datos de Medicamentos, <https://botplusweb.portalfarmacia.com/>
59. Ministerio de Sanidad, Servicios Sociales e Igualdad. Listado de medicamentos afectados por el Real Decreto Ley 8/2010, modificado por el Real Decreto Ley 9/2011. <http://www.msssi.gob.es/profesionales/farmacia/notasInfor.htm>
60. Ministerio de Sanidad Servicios Sociales e Igualdad: Información orientativa sobre los factores de conversión del PVL a PVP y PVP IVA, aplicables a partir de 1 de julio de 2010 (2010). <http://www.msssi.gob.es/profesionales/farmacia/pdf/margenesFactoresConversion.pdf>
61. Ministerio de Sanidad, Servicios Sociales e Igualdad: Factores de conversión de PVL a PVP y PVPi a julio 2010. RD-ley 4/2010 de 26 de marzo - BOE 27 de marzo., <http://www.msssi.gob.es/profesionales/farmacia/notasInfor.htm>
62. Cabello, P., Zozaya, N., Villoro, R., Hidalgo-Vega, Á: Estimación del coste de administración de Rituximab para el tratamiento de Linfomas No Hodgkin en hospitales de día del SNS. Presented at the las XXXV Jornadas de Economía de la Salud, Granada (2015)
63. Alonso-Babarro, A., Bruera, E., Varela-Cerdeira, M., Boya-Cristia, M.J., Madero, R., Torres-Vigil, I., De Castro, J., Gonzalez-Baron, M.: Can this patient be discharged home? Factors associated with at-home death among patients with cancer. *J.*

- Clin. Oncol. **29**, 1159–1167 (2011). <https://doi.org/10.1200/JCO.2010.31.6752>
64. Alonso-Babarro, A., Astray-Mochales, J., Dominguez-Berjon, F., Genova-Maleras, R., Bruera, E., Diaz-Mayordomo, A., Cortes, C.: C.: The association between in-patient death, utilization of hospital resources and availability of palliative home care for cancer patients. *Palliat. Med.* **27**, 68–75 (2013). <https://doi.org/10.1177/0269216312442973>
65. Gómez-Batiste, X., Porta-Sales, J., Espinosa-Rojas, J., Pascual-López, A., Tuca, A., Rodriguez, J.: Effectiveness of palliative care services in symptom control of patients with advanced terminal cancer: a Spanish, multicenter, prospective, quasi-experimental, pre-post study. *J. Pain Symptom Manage.* **40**, 652–660 (2010). <https://doi.org/10.1016/j.jpainsympman.2010.02.026>
66. Calvo-Espinos, C., Ruiz de Gaona, E., Gonzalez, C., Ruiz de Galarraga, L., Lopez, C.: Palliative sedation for cancer patients included in a home care program: a retrospective study. *Palliat. Support. Care.* 1–6 (2014)
67. Alonso-Babarro, A., Varela-Cerdeira, M., Torres-Vigil, I., Rodríguez-Barrientos, R., Bruera, E.: At-home palliative sedation for end-of-life cancer patients. *Palliat. Med.* **24**, 486–492 (2010). <https://doi.org/10.1177/0269216309359996>
68. WHO Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health: WHOCC - ATC/DDD Index, [http://www.whocc.no/atc\\_ddd\\_index/](http://www.whocc.no/atc_ddd_index/)
69. Erlenwein, J., Geyer, A., Schlink, J., Petzke, F., Nauck, F., Alt-Epping, B.: Characteristics of a palliative care consultation service with a focus on pain in a German university hospital. *BMC Palliat. Care* **13**, 45 (2014). <https://doi.org/10.1186/1472-684X-13-45>
70. Sociedad Española de Cuidados Paliativos (SECPAL): Guía de Cuidados Paliativos. <http://www.secpal.com/%5C%5CDocumentos%5CPaginas%5Cguiaep.pdf>
71. González Barón, M., Gómez Raposo, C., Vilches Aguirre, Y.: The last phase in the progressive neoplastic disease: care at the end-of-life, refractory symptoms and sedation. *Med. Clín.* **127**, 421–428 (2006)
72. Ortega-Ortega, M., Montero-Granados, R., Romero-Aguilar, A.: Factores sociodemográficos y clínicos asociados a la recepción de cuidado informal en pacientes con neoplasia hematológica: estudio basado en las diferentes etapas del tratamiento. *Rev. Esp. Salud Pública* **89**, 203–215 (2015)
73. van den Berg, B., Brouwer, W.B.F., Koopmanschap, M.A.: Economic valuation of informal care. *Eur. J. Health Econ. Former. HEPAC.* **5**, 36–45 (2004). <https://doi.org/10.1007/s10198-003-0189-y>
74. Ministerio de Sanidad, Servicios Sociales e Igualdad. Secretaría de Estado de Servicios Sociales e Igualdad. IMSERSO: Informe 2014. Las Personas Mayores en España. Datos estadísticos y Estatales y por Comunidades Autónomas (2015). [http://www.imserso.es/InterPresent1/groups/imserso/documents/binario/22029\\_info2014pm.pdf](http://www.imserso.es/InterPresent1/groups/imserso/documents/binario/22029_info2014pm.pdf)
75. Grossman, M.: The demand for health: a theoretical and empirical investigation. Columbia Univ. Press [u.a.], New York, NY (1972)
76. Oliva-Moreno, J.: Loss of labour productivity caused by disease and health problems: what is the magnitude of its effect on Spain's Economy? *Eur. J. Health Econ.* **13**, 605–614 (2012). <https://doi.org/10.1007/s10198-011-0344-9>
77. Weisbrod, B.A.: The Valuation of Human Capital. *J. Polit. Econ.* **69**, 425–436 (1961)
78. van Hout, W.B.: den: The value of productivity: human-capital versus friction-cost method. *Ann. Rheum. Dis.* **69**, i89–i91 (2010). <https://doi.org/10.1136/ard.2009.117150>
79. Instituto Nacional de Estadística: Media de los cuatro trimestres del año. Activos por sexo y grupo de edad. Valores absolutos y porcentajes respecto del total de cada sexo. <http://www.ine.es/jaxiT3/Tabla.htm?t=4731&L=0>
80. Instituto Nacional de Estadística: Resultados Nacionales: Ganancia media anual por trabajador. Encuesta anual de estructura salarial. Serie 2008–2013. <http://www.ine.es/jaxiT3/Tabla.htm?path=/t22/p133/cno11/serie/10/&file=02005.px&L=0>
81. Seguridad Social: Trabajadores. Prestaciones/Pensiones de Trabajadores. Incapacidad temporal. Régimen General. Nacimiento del derecho/Duración/Pérdida o suspensión/Extinción. [http://www.seg-social.es/Internet\\_1/Trabajadores/PrestacionesPension10935/Incapacidadtemporal/RegimenGeneral/Nacimientoderech28368/6394](http://www.seg-social.es/Internet_1/Trabajadores/PrestacionesPension10935/Incapacidadtemporal/RegimenGeneral/Nacimientoderech28368/6394)
82. Instituto Nacional de Estadística: Estadística del Padrón Continuo. Datos provisionales a 1 de enero de 2016. Mujeres. <http://www.ine.es/jaxi/Datos.htm?path=/t20/e245/p04/provi/10/&file=0000002.px>
83. Instituto Nacional de Estadística: Resultados Nacionales: Ganancia media anual por trabajador según sexo y edad. Encuesta anual de estructura salarial. Serie 2008–2014 (2014). <http://www.ine.es/jaxi/Datos.htm?path=/t22/p133/cno11/serie/10/&file=02005.px>
84. Instituto Nacional de Estadística: Encuesta de estructural salarial. Año 2014. Ganancia media por hora por trabajador: Trabajadores de los servicios de restauración, personales, protección y vendedores. <http://www.ine.es/jaxi/Datos.htm?path=/t22/p133/a2014/10/&file=09002.px>
85. Krol, M., Papenburg, J., van Exel, J.: Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies. *PharmacoEconomics.* **33**, 123–135 (2015). <https://doi.org/10.1007/s40273-014-0218-y>
86. Goodrich, K., Kaambwa, B., Al-Janabi, H.: The inclusion of informal care in applied economic evaluation: a review. *Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res.* **15**, 975–981 (2012). <https://doi.org/10.1016/j.jval.2012.05.009>
87. Ministerio de Sanidad, Servicios Sociales e Igualdad. Instituto de Información Sanitaria. Registro de altas—CMBD. CIE9: 183 (2014). <http://pestadistico.inteligenciadegestion.mssi.es/publicosns>
88. Ministerio de Sanidad, Servicios Sociales e Igualdad. Instituto de Información Sanitaria. Registro de altas—CMBD. CIE9: 183. Unidad de cuidados paliativos (2014). <http://pestadistico.inteligenciadegestion.mssi.es/publicosns>
89. Instituto de Mayores y Servicios Sociales (IMSERSO): INFORME 2014. Las personas Mayores en España. Datos Estadísticos Estatales y por Comunidades Autónomas (2014). [http://www.imserso.es/InterPresent1/groups/imserso/documents/binario/22029\\_info2014pm.pdf](http://www.imserso.es/InterPresent1/groups/imserso/documents/binario/22029_info2014pm.pdf)

## Affiliations

**Laura Delgado-Ortega<sup>1</sup> · Almudena González-Domínguez<sup>2</sup> · Josep María Borrás<sup>3</sup> · Juan Oliva-Moreno<sup>4</sup> · Eva González-Haba<sup>5</sup> · Salomón Menjón<sup>6</sup> · Pedro Pérez<sup>7</sup> · David Vicente<sup>8</sup> · Luis Cordero<sup>1</sup> · Margarita Jiménez<sup>2</sup> · Susana Simón<sup>1</sup> · Álvaro Hidalgo-Vega<sup>4</sup> · Carlota Moya-Alarcón<sup>1</sup>**

Almudena González-Domínguez  
almudena.gonzalez@weber.org.es

Josep María Borrás  
jmborras@ub.edu

Juan Oliva-Moreno  
Juan.OlivaMoreno@uclm.es

Eva González-Haba  
eva.gonzalezhaba@salud.madrid.org

Salomón Menjón  
smenjonb@gmail.com

Pedro Pérez  
pedro.perez@salud.madrid.org

David Vicente  
david.vicente.sspa@juntadeandalucia.es

Luis Cordero  
LuisAngel.Cordero@astrazeneca.com

Margarita Jiménez  
margarita.jimenez@weber.org.es

Susana Simón  
susana.simon@astrazeneca.com

Álvaro Hidalgo-Vega  
alvaro.hidalgo@uclm.es

Carlota Moya-Alarcón  
carlota.moya@astrazeneca.com

<sup>1</sup> AstraZeneca Farmacéutica Spain, Serrano Galvache, 56, Building Álamo, Madrid, Spain

<sup>2</sup> Weber, Majadahonda, Madrid, Spain

<sup>3</sup> Clinical Sciences Department, University of Barcelona, L'Hospital de Llobregat, Barcelona, Spain

<sup>4</sup> Universidad de Castilla-La Mancha – Campus de Toledo, Toledo, Spain

<sup>5</sup> Hospital General Universitario Gregorio Marañón, Madrid, Spain

<sup>6</sup> Hospital Universitario Virgen de las Nieves, Granada, Spain

<sup>7</sup> Hospital Clínico Universitario, Madrid, Spain

<sup>8</sup> Hospital Universitario Virgen Macarena, Sevilla, Spain